Table 4 Clinical symptoms observed among SCD patients with the FVL G1691A and prothrombin G20210A mutations versus SCD patients without these mutations. Results are expressed as frequency and percentages
FVL mutant (N = 20) | FVL wild (N = 97) | P-value | Prothrombin mutant (N = 8) | Prothrombin wild (N = 109) | P value | |
|---|---|---|---|---|---|---|
Joints pain | 16 (80%) | 41 (42.2%) | 0.0132 | 4 (50%) | 55 (50.4%) | NSa |
Chest pain | 18 (90%) | 52 (53.6%) | 0.006 | 4 (50%) | 57 (52.2%) | NS |
Abdominal pain | 14 (70%) | 48 (49.5%) | 0.0311 | 4 (50%) | 61 (55.9%) | NS |
Splenomegaly | 18 (90%) | 53 (54.6%) | 0.0071 | 3 (37.5%) | 49 (44.9%) | NS |
Frequency of Blood transfusion (no./year) | ||||||
0–2 | 2 (10%) | 21 (21.6%) | NS | 1 (12.5%) | 29 (26.6%) | NS |
3–5 | 3 (15%) | 7 (7.2%) | 0.047 | 2 (25%) | 45 (41.3%) | NS |
6–9 | 11 (55%) | 4 (4.1%) | 0.018 | 4 (50%) | 23 (21.1%) | 0.003 |
≥ 10 | 1 (5%) | 0 (0%) | NS | ------- | ------- | ------- |